C. Fernandes (Sao Paulo/Sp, Brazil), M. Delcroix (Leuven, Belgium), P. Hassoun (Baltimore, United States of America), H. Ghofrani (Giessen, Germany)
Evaluation of a novel clinic for management of Chronic Thromboembolic Pulmonary Disease (CTED) and associated Pulmonary Hypertension (CTEPH). A. Roddick (London, United Kingdom)
| |
Quality of life and physical functioning in chronic thromboembolic pulmonary hypertension (CTEPH): the impact of treatment D. Cavalet Blanco (PORTO ALEGRE/RS, Brazil)
| |
Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension E. Schwarz (Zürich, Switzerland)
| |
The use of new anticoagulants in CTEPH F. Gavilanes Oleas (Sao Paulo/Sp, Brazil)
| |
Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment E. Vrigkou (Athens, Greece)
| |
Pulmonary perfusion changes after Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension A. Hachulla (Geneva, Switzerland)
| |
Liquid biopsy for Chronic Thromboembolic Pulmonary Hypertension: Circulating microRNA profile by Next Generation Sequencing A. Todorovic Fabro (Ribeirao Preto/Sp, Brazil)
| |
Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia T. Martynyuk (Moscow, Switzerland)
| |
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) L. Nicod (Lausanne, Switzerland)
| |
Fluid challenge test and pulmonary haemodynamics in patients with systemic sclerosis M. D'Alto (Napoli, Na, Italy)
| |
Incidence of new pulmonary hypertension and determining factors during follow-up of patients with systemic sclerosis after negative right heart catheterisation S. Harutyunova (Heidelberg, Germany)
| |
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal M. Hoeper (Hannover, Germany)
| |
Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension K. Swinnen (Leuven, Belgium)
| |
PHA-UK living with Pulmonary Hypertension 2016 Survey C. Billings (Sheffield, United Kingdom)
| |
Evaluation of thyroid function in pulmonary arterial hypertension G. Cueto Robledo (México D.F, Mexico)
| |
Undifferentiated connective tissue disease at risk for systemic sclerosis: is heart function already impaired? M. D'Alto (Napoli, Na, Italy)
| |
VENTASWITCH study: Switching from Ventavis (iloprost) V10 to V20 improves inhalation behaviour in patients with pulmonary arterial hypertension (PAH) M. Richter (Giessen, Germany)
| |
Pregnancy in PAH associated with congenital heart disease: 6-year clinical cases series from the referral center A. Bautin (St Petersburg, Russian Federation)
| |
Managing pregnancy in pulmonary hypertension using a multi-professional approach: a 16-year experience in a specialist referral centre L. ten Klooster (Nieuwegein, Netherlands)
| |
Modern management of portopulmonary hypertension in children : case series of an expert center F. Lador (Genève 14, Switzerland)
| |